Skip to content

Evaluation of PDL laser for the treatment of cutaneous leishmaniasis

Clinical trial for the Comparison of the effect of PDL laser and injection of glucantime in the treatment of cutaneous lesions of leshmaniasis patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014072018536N1
Enrollment
38
Registered
2017-03-21
Start date
2017-01-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group 1: For one of the lesions, glucantime (vial 1gr/5cc) will be injected intralesional with insulin syringe. The interval between the injections will be one week until
Treatment - Drugs
Treatment - Devices
Intervention group 1: For one of the lesions, glucantime (vial 1gr/5cc) will be injected intralesional with insulin syringe. The interval between the injections will be one week until the lesion will
Intervention group 2: The other lesion will be treated with PDL laser(N light, model A00-0159) with the setting of 7j/cm2 fluence, and 5cm spot size. Laser therapy will be continued with 2 weeks inter

Sponsors

Dr Radmanesh clinic
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 5-55 years; having at least 2 leishmania lesion on the everywhere of body skin with positive direct smear for leishman body. Exclusion criteria: Pregnancy; lactation; using any other treatments before the beginning of the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Induration index. Timepoint: Before the begionning of the study, Every 2 weeks for 10 weeks. Method of measurement: Physical examination by dermatologist.

Secondary

MeasureTime frame
Post inflammatory hyperpigmantation. Timepoint: Every 2 weeks for 10 weeks. Method of measurement: Physical examination by dermatologist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Omidian

Ahvaz Jondishapur University of Medical Sciences

Omidian.e@ajums.ac.ir+98 33302058

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026